• Acura Pharmaceuticals amended its loan schedule under a secured promissory note with Abuse Deterrent Pharma dated Nov. 10, 2022.
• The amendment adds loans through Loan #62 dated June 24, 2026, lifting total aggregated principal to $ 10.69 million.
• The original note principal was $ 2.32 million, with an additional $ 7.08 million in loans scheduled from Dec. 22, 2022 through Dec. 31, 2025.
• Recent 2026 borrowings include multiple $ 100,000 advances, with Loan #62 increasing principal by $ 200,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acura Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-078839), on June 29, 2026, and is solely responsible for the information contained therein.